Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 9/20 | 0.50 |
| ▸ | GALR2 | O43603 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | ABCG2 | Q9UNQ0 | 4/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.44 |
| ▸ | TSHR | P16473 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.44 |
| ▸ | FBP1 | P09467 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8932196 | 0.84 | EGFR (0.60) | EGFRGALR2LMNAPOLBABCG2 | |
| SCHEMBL15929508 | 0.84 | EGFR (0.49) | EGFRGALR2LMNAPOLBABCG2 | |
| SCHEMBL8932198 | 0.82 | EGFR (0.64) | EGFRGALR2LMNAPOLBABCG2 | |
| SCHEMBL20412178 | 0.81 | GAA (0.44) | EGFRABCG2CYP3A4TSHRFBP1 | |
| SCHEMBL29029701 | 0.81 | FBP1 (0.43) | EGFRLMNAABCG2FBP1 | |
| SCHEMBL14579636 | 0.80 | GAA (0.43) | EGFRABCG2CYP3A4TSHRGAA | |
| SCHEMBL8986212 | 0.79 | CYP1A2 (0.54) | EGFRLMNACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28755534 | 0.79 | GAA (0.49) | EGFRLMNACYP3A4TSHRGAA | |
| SCHEMBL14579634 | 0.79 | GAA (0.42) | EGFRABCG2CYP3A4TSHRGAA | |
| SCHEMBL29029705 | 0.79 | ABCG2 (0.43) | EGFRABCG2FBP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8188274-B2 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-05-29 | — | — | US | disclosed |
| US-8067593-B2 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-11-29 | — | — | US | disclosed |
| US-20110207929-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | US | disclosed |
| US-20110207932-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207932-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | EGFR, CNKSR1, ERBB2 | EGFR 1/4885GALR2 1255/4885LMNA 4013/4885 |
| US-20110207929-A1 | Process for preparing aminocrotonylamino-substituted quinazoline derivatives | EGFR, CNKSR1, ERBB2 | EGFR 1/4885GALR2 1255/4885LMNA 4013/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.